Recombinant Human TAFA-2

Description :
FAQ COA 已发表文献 TAFA2 also named FAM19A2, is a secreted, 11 kDa member of the FAM19/TAFA family of chemokine-like proteins. It is synthesized as a 131 amino acid (aa) precursor that contains a 30 aa signal sequence and a 101 aa mature chain. Like other members of the FAM19/TAFA family, with the exception of TAFA5, mature TAFA1 contains 10 regularly spaced cysteine residues that follow the pattern CX7CCX13CXCX14CX11CX4CX5CX10C, where C represents a conserved cysteine residue and X represents any noncysteine amino acid. Human TAFA2 is 97% aa identical to mouse TAFA2. The biological functions of TAFA family members remain to be determined, but there are a few tentative hypotheses. First, TAFAs may modulate immune responses in the CNS by functioning as brain-specific chemokines, and may act with other chemokines to optimize the recruitment and activity of immune cells in the CNS. Second, TAFAs may represent a novel class of neurokines that act as regulators of immune nervous cells. Finally, TAFAs may control axonal sprouting following brain injury. Product Properties Synonyms Chemokine-like protein TAFA-2, FAM19A2, MGC42403, TAFA2 Accession Q8N3H0 GeneID 338811 Source E.coli-derived human TAFA-2protein, Ala31-His131. Molecular Weight Approximately 11.2 kDa. AA Sequence ANHHKAHHVK TGTCEVVALH RCCNKNKIEE RSQTVKCSCF PGQVAGTTRA APSCVDASIV EQKWWCHMQP CLEGEECKVL PDRKGWSCSS GNKVKTTRVT H Tag None Physical Appearance Sterile Filtered White lyophilized (freeze-dried) powder. Purity >95% by SDS-PAGE and HPLC analyses. Biological Activity The biological activity is determined by its ability to enhance neurite outgrowth of E16-E18 rat embryonic cortical neurons. recombinant human TAFA-2, immobilized at 6-24 g/mL on a 96 well plate, is able to significantly enhance neurite outgrowth. Fully biologically active when compared to standard. Endotoxin Formulation Lyophilized from a 0.2 m filtered concentrated solution in 2 PBS, pH 7.4. Reconstitution We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at -20. Further dilutions should be made in appropriate buffered solutions.